ijms-logo

Journal Browser

Journal Browser

Molecular Advances and Therapeutic Strategies in Renal Failure

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (20 November 2024) | Viewed by 5044

Special Issue Editor


E-Mail Website
Guest Editor
Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy
Interests: renal failure; Anderson Fabry disease; vasculopaties
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue titled “Molecular Advances and Therapeutic Strategies in Renal Failure” will mainly cover several aspects regarding molecular and/or cellular mechanisms of renal cell injury leading to (acute or chronic) renal failure, providing us with a platform to potentially build/design specific therapeutic strategies that can prevent/cure those syndromes which are commonly faced by Nephrologists. The increase in their prevalence is due to the populations’ average age progressively increasing and; diabetic and cardiovascular diseases also increasing worldwide; and the large use/abuse of nephrotoxic drugs or agents, such as, for example, radiocontrast media administration.

This Special Issue is also open to considering manuscripts containing novel (including molecular) findings and/or reports (regarding novel therapeutic strategies) regarding patients undergoing dialysis, as well as regarding different genetic (renal) diseases that are often faced by Nephrologists (but also by other Specialists too), such as ADPKD, Alport’s Syndrome and Anderson-Fabry Disease, which can all often lead to chronic renal failure.

Prof. Dr. Michele Andreucci
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • intracellular signaling
  • cell death
  • cell survival
  • gene
  • treatment
  • mortality
  • uremia
  • dialysis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

21 pages, 2030 KiB  
Review
Anemia and Mineral Bone Disorder in Kidney Disease Patients: The Role of FGF-23 and Other Related Factors
by Nazareno Carullo, David Sorbo, Teresa Faga, Sara Pugliese, Maria Teresa Zicarelli, Davide Costa, Nicola Ielapi, Yuri Battaglia, Antonio Pisani, Giuseppe Coppolino, Davide Bolignano, Ashour Michael, Raffaele Serra and Michele Andreucci
Int. J. Mol. Sci. 2024, 25(23), 12838; https://doi.org/10.3390/ijms252312838 - 29 Nov 2024
Cited by 1 | Viewed by 1453
Abstract
Anemia and mineral and bone disorder (MBD) are significant complications of chronic kidney disease (CKD). The erythropoietin (Epo) pathway plays a key role in both of these processes in CKD. Another molecule that plays an important role in CKD-MBD is fibroblast growth factor [...] Read more.
Anemia and mineral and bone disorder (MBD) are significant complications of chronic kidney disease (CKD). The erythropoietin (Epo) pathway plays a key role in both of these processes in CKD. Another molecule that plays an important role in CKD-MBD is fibroblast growth factor (FGF)-23, whose main role is to maintain serum phosphate levels in the normal range, acting via its co-receptor Klotho; however, its activity may also be related to anemia and inflammation. In this review, the regulation of Epo and FGF-23 and the molecular mechanisms of their action are outlined. Furthermore, the complex interaction between EPO and FGF-23 is discussed, as well as their association with other anemia-related factors and processes such as Klotho, vitamin D, and iron deficiency. Together, these may be part of a “kidney–bone marrow–bone axis” that promotes CKD-MBD. Full article
(This article belongs to the Special Issue Molecular Advances and Therapeutic Strategies in Renal Failure)
Show Figures

Figure 1

26 pages, 2013 KiB  
Review
Focus on Mitochondrial Respiratory Chain: Potential Therapeutic Target for Chronic Renal Failure
by Yi Wang, Jing Yang, Yu Zhang and Jianhua Zhou
Int. J. Mol. Sci. 2024, 25(2), 949; https://doi.org/10.3390/ijms25020949 - 12 Jan 2024
Cited by 1 | Viewed by 2746
Abstract
The function of the respiratory chain is closely associated with kidney function, and the dysfunction of the respiratory chain is a primary pathophysiological change in chronic kidney failure. The incidence of chronic kidney failure caused by defects in respiratory-chain-related genes has frequently been [...] Read more.
The function of the respiratory chain is closely associated with kidney function, and the dysfunction of the respiratory chain is a primary pathophysiological change in chronic kidney failure. The incidence of chronic kidney failure caused by defects in respiratory-chain-related genes has frequently been overlooked. Correcting abnormal metabolic reprogramming, rescuing the “toxic respiratory chain”, and targeting the clearance of mitochondrial reactive oxygen species are potential therapies for treating chronic kidney failure. These treatments have shown promising results in slowing fibrosis and inflammation progression and improving kidney function in various animal models of chronic kidney failure and patients with chronic kidney disease (CKD). The mitochondrial respiratory chain is a key target worthy of attention in the treatment of chronic kidney failure. This review integrated research related to the mitochondrial respiratory chain and chronic kidney failure, primarily elucidating the pathological status of the mitochondrial respiratory chain in chronic kidney failure and potential therapeutic drugs. It provided new ideas for the treatment of kidney failure and promoted the development of drugs targeting the mitochondrial respiratory chain. Full article
(This article belongs to the Special Issue Molecular Advances and Therapeutic Strategies in Renal Failure)
Show Figures

Figure 1

Back to TopTop